Dr. Luis Montuenga Badía
Director of the Biomarkers and New Therapeutic Targets in Lung Cancer Group, Solid Tumors Program. Preferential dedication to the search for new molecular tools for the diagnosis and treatment of lung cancer.
Full professor in Cell Biology.
Graduated in Science from the University of Navarra in 1981 with honors and received his Ph.D. in 1985 from the same university.
He has carried out postdoctoral research stays at the Hammersmith Hospital in London (UK) and at the National Cancer Institute (NIH) in Bethesda (USA).
His research focuses on the search for new molecular tools for the diagnosis and treatment of lung cancer.
He directs as principal investigator of the Biomarkers and New Therapeutic Targets in Lung Cancer Research Group, within the Solid Tumors Program at Cima Universidad de Navarra.
He is a Full-Professor of Cell Biology at the Faculties of Science and Medicine of the University of Navarra.
Dean of the Faculty of Science at the University of Navarra since June 2014.
He is part of the Cima University of Navarra since its inception.
He has registered six patents, one of which has been licensed to a Spanish biotechnology company.
He has been PI in numerous regional, national and international competitive projects, as well as in collaborations with companies. Of note are the competitive projects funded by: European Union, Instituto de Salud Carlos III, Government of Navarra and other companies and foundations such as the Spanish Association Against Cancer.
AREAS OF INTEREST
- Characterization of molecular alterations in lung carcinogenesis to identify potential diagnostic and prognostic biomarkers.
- Biomarkers in the context of early detection (screening).
- Identify new targets and therapeutic strategies in lung cancer.
- Use of genomic technologies to identify and validate new molecular targets in tumors with few therapeutic options.
As an educator
He is Full Professor of Cell Biology at the Faculties of Science and Medicine of the University of Navarra.
Dean of the Faculty of Science of the University of Navarra since June 2014.
He has supervised 22 doctoral theses, all of them recognized with the highest qualification.
As a researcher
He is the author of 206 articles in his specialty and has given numerous national and international conferences and seminars.
He has been a member of the European Early Lung Cancer (EU-ELCG) and a partner of the European CURELUNG Consortium for genomics and epigenomics of lung cancer.
He is a member of the Staging and Prognostic Factors Committee of the AISLC - International Association for the Study of Lung Cancer. Since 2021, he is also part of the NIH-funded INTEGRAL consortium to study biomarkers in the context of early detection of lung cancer.
He is the group leader and coordinator of the Respiratory Tract Tumors Program at the Center for Biomedical Research in Cancer Network (CIBERONC).
- Member of the European Early Lung Cancer Group (EU-ELCG).
- Member of the Lung Cancer Area at the Clínica Universidad de Navarra.
- Member of the European CURELUNG Consortium.
- Member of the INTEGRAL consortium since 2021.
- Group Leader of CIBERONC.
- In 2021: First Cancer Research Award granted by the Lung Cancer Ambition Alliance Spain.
- In 2018: First Prize, "Professor Durántez" awarded by the L.A.I.R. Foundation.
- From 2008 to 2011: Vice-Rector for Research, University of Navarra.
Latest scientific publications
- DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity Sep 28, 2022 | Magazine: The Journal of Experimental Medicine
- Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System May 31, 2022 | Magazine: Cancers